PEG-MGF: research

PEG-MGF dosage

Typical reported dose: 200 mcg twice a week

• 200 mcg twice weekly: 200 mcg per injection wednesday and Saturday, under the skin. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 300–400 mcg on training days: Up to 300 mcg/day, sometimes 400 mcg/day on training days, sometimes on consecutive days, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 120 mcg after training: 120 mcg per reported injection after workouts; days per week not stated, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 200–400 mcg, 2–3 times weekly: 200–400 mcg per injection 2–3 times per week, under the skin. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 1,000 mcg twice weekly: 1,000 mcg per session, divided into twenty 50 mcg injections twice weekly, with the second session about 3–4 days later, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• Nasal experiment, 200 mcg twice daily: 200 mcg per administration, 400 mcg/day total twice daily, nasal spray. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

PEG-MGF side effects and risks

Reported side effects

• Injection-site pain, bruising or bleeding: No compound specific human rate. These are injection route risks., moderate. Persistent pain, a growing lump or bleeding needs assessment. (source)
• Infection or tissue injury from an unregulated injection: No MGF specific rate or denominator was found., serious. Spreading redness, fever or severe pain needs urgent assessment. (source)
• Allergic or immune reaction: FDA flags possible immune reactions to PEG MGF; no human rate is available., serious. Breathing trouble, swelling or fainting requires emergency care. (source)
• Blood-sugar changes, theoretical: No direct human evidence for this peptide. Risk is extrapolated from the wider hormone drug setting., serious. Check glucose with symptoms, particularly with insulin or glucose-lowering pills. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, fainting or widespread hives after exposure: Stop exposure and call emergency services immediately. Use prescribed emergency allergy treatment if available.
• Confusion, seizure, unconsciousness or low blood sugar that does not resolve: Get emergency care. Do not give food or drink to someone who cannot swallow safely.
• Hot, spreading injection-site redness, fever, pus or rapidly worsening pain: Stop injections and seek urgent medical assessment for infection or tissue injury.
• Chest pain, severe breathlessness, collapse or new neurological symptoms: Call emergency services now. Tell the team about all peptides and other drugs used.
• Severe muscle pain or swelling with numbness after a muscle injection: Seek emergency care for possible bleeding or pressure injury in the muscle.

Who should avoid it

• under18: Precaution: no pediatric dosing or safety study of this synthetic peptide was found.
• pregnant: Precaution: pregnancy and fetal safety have not been studied.
• breastfeeding: Precaution: breast-milk transfer and infant effects are unknown.
• tryingToConceive: Precaution: fertility effects and a safe time to stop before conception are unknown.
• activeCancer: Precaution: related MGF peptide promoted prostate cancer-cell growth. Whether PEG-MGF shares this effect is unknown.
• cancerHistory: Review prior cancer with the treating clinician. A laboratory cell-growth signal exists; human recurrence risk is unknown.
• diabetes: Blood-sugar effects are uncharacterized. Insulin and some diabetes pills already raise low-sugar risk.
• heartCondition: Animal heart findings do not establish human safety. New swelling or breathlessness needs assessment.
• kidneyDisease: Clearance in kidney disease is unknown. Kidney problems also change blood-sugar and bleeding risks.
• liverDisease: No dosing adjustment is established. Liver disease can complicate interpretation of IGF-1 tests and bleeding risk.
• bleedingDisorder: Muscle injections can cause bleeding or a deep collection of blood. This is a route risk, not a proven peptide effect.
• testedAthlete: WADA 2026 prohibits mechano growth factors at all times under S2.3. PEG modification does not make an analogue permitted.
• other: Avoid a substance that previously caused a serious allergic reaction. Actual vial ingredients may be uncertain.
• other: Avoid a PEG-containing product after confirmed PEG allergy. Product identity and the PEG component may be poorly characterized.

Interactions

• Insulin: Insulin causes low blood sugar. Any added effect of this peptide is untested; symptoms need a glucose check.
• Sulfonylureas and meglitinides: These pills can cause low blood sugar. No interaction study with MGF or PEG-MGF establishes a safe combination.
• Growth hormone, IGF-1 and GH-releasing drugs: Stacking adds untested growth and metabolic exposures. Human safety and claims about optimal spacing are unproven.
• Anticoagulants and antiplatelet drugs: Muscle punctures can bleed or bruise more on these drugs. A direct chemical interaction with the peptide is unknown.
• Unpegylated MGF: Related products may be duplicated in a stack. No human study establishes combined exposure or benefit.

Product quality risks

• No independent market survey of PEG-MGF purity, dose, sterility or endotoxin was found.
• Related MGF products have contained modified peptide or protein constructs. These findings do not establish what is in a PEG-MGF vial.
• Unregulated vials may have the wrong identity or amount, impurities, microbes or bacterial toxins. No compound-specific contamination rate is established.
• FDA flags possible immune reactions, peptide impurities and difficulty characterizing PEG-MGF. A claimed purity percentage cannot resolve these issues.

How PEG-MGF works

PEG-MGF attaches a polymer called PEG to an MGF-related fragment. The aim is longer exposure. Related fragments affect growth signals in some lab experiments, but results conflict and do not establish how PEG-MGF works in people.

• MGF E-domain signalling: Some cell studies report growth or movement signals through ERK. An independent study failed to reproduce key effects.
• IGF-1 receptor: A direct receptor target for the isolated E peptide is not established. It is not interchangeable with mature IGF-1.

Half-life: No human half-life has been established.